BioCryst Pharmaceuticals (NASDAQ: BCRX) is making a big change within its C-suite. The company announced Thursday that it has appointed a new CFO, Anthony Doyle. It was not immediately clear when his tenure would begin.
Doyle comes to BioCryst from privately held research company Worldwide Clinical Trials Holdings, where he also filled the post of CFO starting in 2014. Prior to that, he was employed in a variety of financial positions at General Electric, and was CFO of World Book, owned by Warren Buffett’s investment vehicle Berkshire Hathaway.
For his labors at BioCryst, Doyle is to be paid $480,000 per year. He will also be eligible for bonuses under the company’s annual incentive plan and will receive a $50,000 signing bonus. The latter is to be paid on or before the six-month anniversary of his starting date. Finally, he will also be eligible for stock options.
Although BioCryst has one drug on the market, flu treatment Rapivab, the company is essentially still a clinical-stage biotech.
That said, it recently filed for regulatory approval to market its drug berotralstat, which treats hereditary angioedema (deep swelling of the tissue under the skin). However, the company effort that has attracted the most interest is galidesivir, an early clinical-stage drug that might be effective in treating the SARS-CoV-2 coronavirus that’s spreading around the world.
As with many biotechs, BioCryst’s share price has swung around violently at times, and investor caution and care is warranted. On Thursday, it rose by 5%, exceeding the gains of the broader market.
10 stocks we like better than BioCryst Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and BioCryst Pharmaceuticals wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of March 18, 2020
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short June 2020 $205 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.